FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890887054> ?p ?o ?g. }

• W2890887054 endingPage "33231" @default.
• W2890887054 startingPage "33215" @default.
• W2890887054 abstract "// Manoranjan Sahoo 1 , Gajendra K. Katara 1 , Mahmood Y. Bilal 1 , Safaa A. Ibrahim 1 , Arpita Kulshrestha 1 , Sara Fleetwood 1 , Kimiko Suzue 2 and Kenneth D. Beaman 1 1 Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA 2 Department of Pathology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA Correspondence to: Kenneth D. Beaman, email: kenneth.beaman@rosalindfranklin.edu Keywords: tumor microenvironment (TME); breast tumor; CD8 + T cells; hematopoietic stem cells (HSC); vacuolar ATPase Received: July 05, 2018      Accepted: August 13, 2018      Published: September 04, 2018 ABSTRACT The interaction of recruited immune effector cells and cancer cells within tumor microenvironment (TME) shapes the fate of cancer progression and metastasis. Many cancers including breast cancer, express a specific vacuolar ATPase (a2V) on their cell surface which acidifies the extracellular milieu helping cancer cell proliferation and metastasis. To understand the role of immune cell-associated-a2V during breast tumor pathogenesis, we knocked-out a2V (KO) from the hematopoietic stem cells (HSC) and generated breast tumors in mice. The a2V-KO mice developed faster growing, larger, and metastatic breast tumors compared to control mice. Further investigation of the TME revealed a significant reduction in the presence of CD4 + and CD8 + T cells in the a2V-KO tumors. Targeted RNA-Seq of the cells of the TME demonstrated that pro-inflammatory cytokines, death receptors, death receptor ligands, and cytotoxic effectors were significantly down-regulated within the a2V-KO TME. Interestingly, analysis of immune cells in the blood, spleen, and thymus of the non-tumor bearing a2V-KO mice revealed a significant decrease in CD4 + and CD8 + T cell populations. For the first time, this study demonstrates that inhibition of V-ATPase expression in HSC leads to a decrease in CD4 + and CD8 + T cell populations and thus promotes breast tumor growth and metastasis." @default.
• W2890887054 created "2018-09-27" @default.
• W2890887054 creator A5010623478 @default.
• W2890887054 creator A5011820693 @default.
• W2890887054 creator A5033861809 @default.
• W2890887054 creator A5037482092 @default.
• W2890887054 creator A5047927083 @default.
• W2890887054 creator A5050650557 @default.
• W2890887054 creator A5064427237 @default.
• W2890887054 creator A5079173122 @default.
• W2890887054 date "2018-09-04" @default.
• W2890887054 modified "2023-09-26" @default.
• W2890887054 title "Hematopoietic stem cell specific V-ATPase controls breast cancer progression and metastasis via cytotoxic T cells" @default.
• W2890887054 cites W1493822493 @default.
• W2890887054 cites W1536303889 @default.
• W2890887054 cites W1933912253 @default.
• W2890887054 cites W1971394915 @default.
• W2890887054 cites W1972825083 @default.
• W2890887054 cites W1973855239 @default.
• W2890887054 cites W1981229930 @default.
• W2890887054 cites W1987000399 @default.
• W2890887054 cites W1989506590 @default.
• W2890887054 cites W1995232616 @default.
• W2890887054 cites W2016486423 @default.
• W2890887054 cites W2020199574 @default.
• W2890887054 cites W2024748688 @default.
• W2890887054 cites W2031382215 @default.
• W2890887054 cites W2053882094 @default.
• W2890887054 cites W2058915875 @default.
• W2890887054 cites W2062562477 @default.
• W2890887054 cites W2062595626 @default.
• W2890887054 cites W2084402806 @default.
• W2890887054 cites W2090687743 @default.
• W2890887054 cites W2096353669 @default.
• W2890887054 cites W2096554723 @default.
• W2890887054 cites W2096771026 @default.
• W2890887054 cites W2098328107 @default.
• W2890887054 cites W2100763293 @default.
• W2890887054 cites W2114664765 @default.
• W2890887054 cites W2116378201 @default.
• W2890887054 cites W2122403898 @default.
• W2890887054 cites W2123393421 @default.
• W2890887054 cites W2130506153 @default.
• W2890887054 cites W2137018390 @default.
• W2890887054 cites W2142112207 @default.
• W2890887054 cites W2143646220 @default.
• W2890887054 cites W2146037312 @default.
• W2890887054 cites W2149109011 @default.
• W2890887054 cites W2149668671 @default.
• W2890887054 cites W2156756006 @default.
• W2890887054 cites W2175250120 @default.
• W2890887054 cites W2211944491 @default.
• W2890887054 cites W2254720258 @default.
• W2890887054 cites W2280443309 @default.
• W2890887054 cites W2291579888 @default.
• W2890887054 cites W2321484930 @default.
• W2890887054 cites W2343796589 @default.
• W2890887054 cites W2465929875 @default.
• W2890887054 cites W2471500324 @default.
• W2890887054 cites W2472879531 @default.
• W2890887054 cites W2547920589 @default.
• W2890887054 cites W2622177763 @default.
• W2890887054 cites W2625996519 @default.
• W2890887054 cites W2767986423 @default.
• W2890887054 cites W2770338041 @default.
• W2890887054 cites W287807773 @default.
• W2890887054 doi "https://doi.org/10.18632/oncotarget.26061" @default.
• W2890887054 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6145706" @default.
• W2890887054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30237863" @default.
• W2890887054 hasPublicationYear "2018" @default.
• W2890887054 type Work @default.
• W2890887054 sameAs 2890887054 @default.
• W2890887054 citedByCount "9" @default.
• W2890887054 countsByYear W28908870542018 @default.
• W2890887054 countsByYear W28908870542020 @default.
• W2890887054 countsByYear W28908870542021 @default.
• W2890887054 countsByYear W28908870542022 @default.
• W2890887054 countsByYear W28908870542023 @default.
• W2890887054 crossrefType "journal-article" @default.
• W2890887054 hasAuthorship W2890887054A5010623478 @default.
• W2890887054 hasAuthorship W2890887054A5011820693 @default.
• W2890887054 hasAuthorship W2890887054A5033861809 @default.
• W2890887054 hasAuthorship W2890887054A5037482092 @default.
• W2890887054 hasAuthorship W2890887054A5047927083 @default.
• W2890887054 hasAuthorship W2890887054A5050650557 @default.
• W2890887054 hasAuthorship W2890887054A5064427237 @default.
• W2890887054 hasAuthorship W2890887054A5079173122 @default.
• W2890887054 hasBestOaLocation W28908870541 @default.
• W2890887054 hasConcept C109159458 @default.
• W2890887054 hasConcept C121608353 @default.
• W2890887054 hasConcept C126322002 @default.
• W2890887054 hasConcept C154317977 @default.
• W2890887054 hasConcept C167672396 @default.
• W2890887054 hasConcept C185592680 @default.
• W2890887054 hasConcept C202751555 @default.
• W2890887054 hasConcept C203014093 @default.
• W2890887054 hasConcept C2776090121 @default.
• W2890887054 hasConcept C2776107976 @default.

• next